A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

Inclusion Criteria: * Male or female participants; age ≥ 18 years * Pathologically confirmed nonsquamous NSCLC that is metastatic, locally advanced, or recurrent with progression * Arm A participants must fulfill one of the following: * Participant has a genetic alteration (mutation or rearrangement) and has received all available targeted therapy. Previous treatment with chemotherapy or PD-1/-L1 therapy is not allowed. * Participant has not received any therapy for the disease under study and standard therapy is refused. * Participant has progressed on PD-1/-L1 therapy (monotherapy or combination regimen). Previous treatment with chemotherapy is not allowed. * Participant has progressed on PD-1/-L1 therapy (monotherapy or combination regimen) and has received less than 4 cycles of carboplatin/pemetrexed and further chemotherapy is appropriate. * Participant has received any number of prior treatments and is without alternative or curative therapy. * Arm B participants must fulfill one of the following: * Participant has a genetic alteration (mutation or rearrangement) and has received all available targeted therapy. Previous treatment with chemotherapy or PD-1/-L1 therapy is not allowed. * Participant has not received any therapy for the disease under study and standard therapy is refused. * Participant has received any number of prior treatments and is without alternative or curative therapy. * Arm 1 and Arm 2 participants must have a sensitizing epiderma…